Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH
AASLD
oral
TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma
European Society for Medical Oncology (ESMO) Congress
Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients
Precison: Lung Cancer R&D Summit
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
International Congress on Targeted Anticancer Therapies
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement
Keystone Symposium – New Frontiers in Understanding Tumor Metabolism
Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640
EORTC-NCI-AACR International Conference
